李氏大药厂Lee's Pharm
李氏大药厂控股有限公司（「李氏大药厂」或「集团」）是一家已上市生物医药公司，于中国医药行业经营超过18年。集团拥有国际视野并结合已在中国建立了稳固的药品发展、临床发展、规管、制造及销售以及市场推广的业务模式，目前在中国推出市场的产品共有十一种。李氏大药厂致力于不同范畴，包括心血管及传染疾病、皮肤医学、肿瘤学、妇科学等多个不同领域。而其它处于不同开发阶段产品亦有超过三十种，包括来自内部研发及近期购买各美国, 欧洲公司及日本的特许及分销权。于二零一零年，李氏大药厂更获亚洲财经杂志《Finance Asia》颁发「2010亚洲最佳公司选举 – (中国区)最佳小型企业」第二名。 于2011年9月李氏大药厂获福布斯选为亚洲最佳二百公司(营业额少于十亿美元)。 李氏大药厂的目标是成为亚洲成功的生物医药集团，提供能治疗疾病，同时改善身体及生活素质。

李氏大药厂的策略性股东，Sigma Tau Group是罗马（意大利）国际领先的医药研究公司。Sigma Tau 进行的研发活动和商业技术与李氏大药厂现时的业务有互补的作用，为李氏大药厂带来重要的业务协同效益。

Lee's Pharmaceutical Holdings Limited (Lee's Pharm or “the Group”) is a public biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets eleven products in the PRC. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies. In 2010, Lee’s Pharm ranked as Best Small-Cap Company in China (Rank 2nd) by Finance Asia. In September 2011, Lee's Pharm has been selected by Forbes as one of Asia's 200 Best Under A Billion Company (turnover less than US$1 billion). The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.
Sigma Tau Group, the leading research-based international pharmaceutical company based in Rome (Italy), is a strategic shareholder of Lee's Pharm. Sigma Tau's ongoing R&D activities and commercial know-how are complementary to the existing business activities of Lee's Pharm and will result in creating significant business synergies for Lee's Pharm.